Hanot Marie, Lohou Elodie, Sonnet Pascal
AGIR, UR 4294, Faculté de Pharmacie, Université de Picardie Jules Verne, 1 Rue des Louvels, 80000 Amiens, France.
Pharmaceuticals (Basel). 2025 Jan 13;18(1):92. doi: 10.3390/ph18010092.
is one of world's most threatening bacteria. In addition to the emerging prevalence of multi-drug resistant (MDR) strains, the bacterium also possesses a wide variety of virulence traits that worsen the course of the infections. Particularly, its ability to form biofilms that protect colonies from antimicrobial agents is a major cause of chronic and hard-to-treat infections in immune-compromised patients. This protective barrier also ensures cell growth on abiotic surfaces and thus enables bacterial survival on medical devices. Hence, as the WHO alerted to the need to develop new treatments, the use of anti-biofilm agents (ABAs) appeared as a promising approach. Given the selection pressure imposed by conventional antibiotics, a new therapeutic strategy has emerged that aims at reducing bacterial virulence without inhibiting cell growth. So-called anti-virulence agents (AVAs) would then restore the efficacy of conventional antibiotics (ATBs) or potentiate the effectiveness of the immune system. The last decade has seen the development of ABAs as AVAs against . This review aims to highlight the design strategy and critical features of these molecules to pave the way for further discoveries of highly potent compounds.
是世界上最具威胁性的细菌之一。除了多重耐药（MDR）菌株的日益流行外，这种细菌还具有多种毒力特性，会使感染病程恶化。特别是，它形成生物膜以保护菌落免受抗菌剂影响的能力，是免疫功能低下患者慢性和难治性感染的主要原因。这种保护屏障还确保细胞在非生物表面生长，从而使细菌能够在医疗设备上存活。因此，正如世界卫生组织提醒需要开发新的治疗方法一样，使用抗生物膜剂（ABA）似乎是一种有前景的方法。鉴于传统抗生素带来的选择压力，一种新的治疗策略应运而生，其目的是在不抑制细胞生长的情况下降低细菌毒力。所谓的抗毒力剂（AVA）将恢复传统抗生素（ATB）的疗效或增强免疫系统的有效性。在过去十年中，已经开发出作为抗……的ABA的AVA。本综述旨在突出这些分子的设计策略和关键特征，为进一步发现高效化合物铺平道路。
